Thalassemia access in Pakistan, the Punjab registry, and where Reserve Meds fits

Regulatory framework and the thalassemia named-patient access pathway in Pakistan, 2026

The Drug Regulatory Authority of Pakistan (DRAP) is the federal regulatory authority that governs medicine registration, manufacturing, and import in Pakistan. The official regulator portal is at www.dra.gov.pk; the locally registered medicines list is at www.dra.gov.pk/registered-drugs. The DRAP-administered One-Stop Industrial and Entrepreneur Services (OIES) portal handles the named-patient and personal-import application stream for reference-authority-approved medicines that are not yet held on the locally registered list at the time the case opens.

The qualifying conditions are stable across the recent regulatory cycle. The medicine must be approved by a recognised reference authority (US Food and Drug Administration or European Medicines Agency qualifies). No locally available alternative is clinically equivalent for the specific patient indication. The treating physician of record takes documented clinical responsibility. Chain of custody is preserved end to end from the source country (the US under Drug Supply Chain Security Act handling for Reserve Meds cases) through international transit to the named dispensing facility. The application is filed by the treating physician and the receiving institutional pharmacy through OIES; Reserve Meds provides the upstream sourcing, chain-of-custody documentation, and international shipping that the institutional pharmacy then attaches to its OIES file.

Tertiary centres and clinical coordination in Pakistan

The Pakistan tertiary referral network that most thalassemia named-patient access cases route through includes Aga Khan University Hospital (AKUH) Karachi, Shaukat Khanum Memorial Cancer Hospital (SKMCH) Lahore and Peshawar, Indus Hospital and Health Network, Children's Hospital and Institute of Child Health Lahore, and Pakistan Institute of Medical Sciences (PIMS) Islamabad. These centres carry the haematology, oncology, neurology, metabolic, infectious-disease, and rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For high-complexity therapies that need specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring, the case is routinely referred to one of these centres from the outset.

For oral, subcutaneous, and standard in-clinic infusion therapies that can be administered in Pakistan once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway shifts to patient travel; the Pakistan tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.

Pakistan pricing reference and payer posture for thalassemia named-patient access, 2026

Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for PKR conversion is 1 USD = 280 PKR. Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately on every quote.

Payer posture in Pakistan for the thalassemia named-patient access pathway is overwhelmingly cash-pay. The relevant federal scheme is Sehat Sahulat Program (provincial) and out-of-pocket spending dominates specialty cases; the portal is at sehat.gov.pk. Public coverage generally does not extend to non-locally-registered specialty named-patient cases. Private health insurance plans (Jubilee, EFU, Adamjee, TPL Life) review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake. International outward remittance for the US drug invoice typically clears under the State Bank of Pakistan Form FE-25 framework for medical-treatment-related transfers; we provide the USD invoice the family then takes to their bank.

Access barriers in the thalassemia named-patient access pathway and how Reserve Meds clears them

The five barriers that most often delay a thalassemia named-patient access case in Pakistan are: (1) Regulatory documentation completeness. The DRAP OIES named-patient application package requires a specific bundle (physician clinical rationale letter, prescription with full strength and quantity, patient identifier, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent). Reserve Meds provides physician-facing templates aligned to the format the reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with US-licensed specialty wholesale partners under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.

(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Pakistan physician are coordinated as a single arc rather than as fragmented vendor handoffs. (5) Funding and remittance mechanics. Cash-pay is the default. For international transfers to the US source we provide an invoice in USD against the case quote; families coordinate the in-country remittance with their bank under the State Bank of Pakistan Form FE-25 framework for medical-treatment-related outbound transfers.

The Reserve Meds operating posture across the five barriers is the same in every Pakistan case: we resolve the operational, regulatory, sourcing, and logistics work; the treating physician of record holds the clinical authority; the family holds the funding and the final go/no-go.

Recent regulatory and access news for the thalassemia named-patient access pathway in Pakistan, 2026

The Drug Regulatory Authority of Pakistan (DRAP) portal at www.dra.gov.pk and the locally registered medicines list at www.dra.gov.pk/registered-drugs are the authoritative source for the current Pakistan listing status of any specific medicine; the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active safety advisory or supply-side shortage signal over the most recent 12-month window. The State Bank of Pakistan medical-remittance framework guidance at sbp.org.pk epd governs FE-25 outward remittance for treatment-related transfers. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.